Tech Company Financing Transactions

Kezar Life Sciences Funding Round

Cormorant Asset Management, Morningside Group and AJU IB Investment joined a $50 million Series B funding round for Kezar Life Sciences. The round was announced by the company on 7/26/2017.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

4000 Shoreline Ct. 300
San Francisco, CA 94080
USA

Phone

(650) 822-5600

Website

www.kezarlifesciences.com

Email Address

[email protected]

Overview

Kezar Life Sciences, a privately held company based in South San Francisco, was founded in 2015 to develop drugs to revolutionize the treatment of autoimmune disorders.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

John Fowler

        

Co-Founder

Jack Taunton

        

President

Christopher Kirk

        

Browse more venture capital transactions:

Prev: 7/26/2017: FilterEasy venture capital transaction
Next: 7/26/2017: Circulation venture capital transaction

Share this article

About Our VC Transactions Data

We report on all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary